Apparently, we're seeing combo dosing from the outset. This has me wondering what the p1a is for? If the combination dose expansion starts from p1a, then, by the definition of a dose expansion study, a cohort should be receiving the optimum combination dosing. Why would this not have the potential to validate CPACS? Surely the clinical trial strategy is one of the many updates presented at the AGM.
RAC Price at posting:
$1.47 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)